DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand?

Development of various vaccines for prostate cancer (PCa) is becoming an active research area. PCa vaccines are perceived to have less toxicity compared with the available cytotoxic agents. While various immune-based strategies can elicit anti-tumour responses, DNA vaccines present increased efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmad, Sarfraz, Sweeney, Paul, Sullivan, Gerald C, Tangney, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502114/
https://www.ncbi.nlm.nih.gov/pubmed/23046944
http://dx.doi.org/10.1186/1479-0556-10-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502114/
https://www.ncbi.nlm.nih.gov/pubmed/23046944
http://dx.doi.org/10.1186/1479-0556-10-9

Ejemplares similares